Country
Netherlands
The European Medicines Agency is recommending approval of Evrysdi (risdiplam) to treat spinal muscular atrophy (SMA) – a rare and often fatal disease affecting neurons in the brain and spinal cord that control muscle movement.
Full text available to subscribers only. Click here for information on subscribing to MedNous.